Baxdrostat Bioavailability and Bioequivalence Study

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 11, 2020

Primary Completion Date

April 29, 2020

Study Completion Date

April 29, 2020

Conditions

Hypertension

Interventions

DRUG

baxdrostat (formerly CIN-107) oral solution

5 mg single dose of baxdrostat given as either a solution or tablet in either the fed or fasted state, depending on the arm of the study

Trial Locations (1)

Medpace, Cincinnati